Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias.

@article{PottHoeck1995PurineAI,
  title={Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias.},
  author={Christiane Pott-Hoeck and Wolfgang Hiddemann},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={1995},
  volume={6 5},
  pages={
          421-33
        }
}
  • C. Pott-Hoeck, W. Hiddemann
  • Published 1 May 1995
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
The purine analogs fludarabine (FAMP), 2-chlorodeoxy-adenosine (2-CDA) and 2-deoxycoformycin (DCF) comprise a novel group of agents with high activity in low-grade lymphoid malignancies. Although all three agents share several mechanisms of action, such as the induction of apoptosis, and toxic effects, such as prolonged immunosuppression, their activity appears to be different in different disorders. While FAMP and possibly also 2-CDA are highly active in chronic lymphocytic leukemia and low… 
Older and new formulations of cladribine. Pharmacology and clinical efficacy in hematological malignancies.
TLDR
Recent data indicate that 2-CdA combined with other cytotoxic agents and monoclonal antibodies show synergistic proapoptotic and cytot toxic activity on lymphoid and myeloid neoplastic cells.
2-chloro-2'-deoxyadenosine: clinical applications in hematology.
TLDR
The anticancer drug 2-chloro-2'-deoxyadenosine (CdA) is exquisitely cytotoxic both to the dividing and to the non-dividing lymphocyte, which supports its use in lymphoproliferative disorders of low-grade malignancy.
Bendamustine in the Treatment of Low-Grade Non-Hodgkin’s Lymphomas
TLDR
The present data suggest bendamustine as a highly effective drug in refractory or relapsing low-grade NHL including CLL and MM and its relevance in the second- and third-line therapy as well as in first-line schedules as a single agent and in combinations will have to be elucidated by further studies.
The developing role of clofarabine in acute leukemias
TLDR
An intriguing aspect of nucleoside analogs thus remains how apparently minor alterations in structure can result in major differences with respect to pharmacology, metabolism, and spectrum of activity.
Evaluation of purine and pyrimidine analogues in human tumor cells from patients with low‐grade lymphoproliferative disorders using the FMCA
TLDR
It is proposed that AraC and gemcitabine may have a role in the treatment of low‐grade NHL, with results indicating that the purine‐ and pyrimidine nucleoside analogues tested may be as active against low-grade NHL as against acute leukemia.
Complications in the treatment of CLL with purine analogues.
The main complications from treatment of CLL with purine analogues are bone marrow depression resulting in cytopenia, immune suppression leading to infections, particularly opportunistic infections,
Clinical status and optimal use of rituximab for B-cell lymphomas.
TLDR
The mechanisms of action of rituximab are reviewed, as well as preclinical data and results of the clinical trials that led to its approval, as the beginning of a promising new era in cancer therapy.
Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.
TLDR
Results of available studies are increasingly highlighting an important future role for fludarabine in the treatment of acute leukaemias and low grade NHL and possibly other lymphoproliferative disorders, particularly when used as a component of combination chemotherapy.
Clastogenic activity of 2-chlorodeoxyadenosine in mammalian somatic cells
TLDR
The results indicate a clastogenic effect of 2-CdA in human lymphocyte cultures and in vivo in BALB/c mice bone marrow cells.
In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia
TLDR
In conclusion, this study demonstrates for the first time the in vitro efficacy of bendamustine in inducing apoptosis in B-CLL cells alone and in combination with fludarabine.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 189 REFERENCES
Low-dose deoxycoformycin in lymphoid malignancy.
  • M. Grever, J. Leiby, +4 authors S. Balcerzak
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1985
TLDR
The demonstration of responses to dCF following failure on standard alkylating agents suggests that dCF may not be cross-resistant with current agents used to treat CLL, and additional studies should be pursued using low-dose dCF in patients with advanced malignancy.
2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug.
TLDR
Pentostatin is valuable for treatment of indolent lymphoid malignancies and may be useful in non-cancer-related lymphocyte research.
2-Chlorodeoxyadenosine treatment of low-grade lymphomas.
  • A. Kay, A. Saven, +4 authors L. Piro
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1992
TLDR
This phase II trial demonstrates that 2-CdA is an effective antilymphocyte, antineoplastic agent with significant activity as a single agent in patients with recurrent or refractory low-grade lymphocytic lymphoma.
2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive Nucleoside.
TLDR
2-CdA resists the action of adenosine deaminase and accumulates in cells with high deoxycytidine kinase and low 5'-nucleotidase activity, and is equally toxic to dividing and nondividing cells and may act by preventing repair of DNA single-strand breaks.
2'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies.
TLDR
Data confirm other reports of the activity of 2CDA in low grade NHL and indicate it may have activity in Hodgkin's disease and there was no demonstrable activity in poor performance status patients or those with extensively pre-treated lymphoplasmacytoid tumours.
2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma.
TLDR
2-CdA is an effective new agent for the treatment of cutaneous T-cell lymphoma and warrants further study both as a single agent and in combination regimens.
An investigation of 2'-deoxycoformycin in the treatment of cutaneous T-cell lymphoma.
TLDR
It is concluded that effective antitumor activity in advanced MF can be achieved with DCF at doses that may not be associated with prohibitive toxicity and would encourage further investigation of this agent in patients with advanced cutaneous T-cell lymphoma.
2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia.
TLDR
2-CDA given by prolonged continuous infusion has clinically significant activity against AML and merits further testing in multidrug regimens for this disease.
Immunosuppressive effects of pentostatin.
TLDR
It is concluded that low doses of dCF can cause persistent immunosuppression though recovery may occur after the drug is stopped, and recovery to normal T- and B-cell numbers and subsets does occur.
Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine.
TLDR
2-chlorodeoxyadenosine may be the most effective therapy available for hairy-cell leukemia and its toxicity may be lower than that of deoxycoformycin, and the responses were achieved with single courses of treatment.
...
1
2
3
4
5
...